Trial Profile

XIENCE Xpedition Everolimus-Eluting Coronary Stent Japan Post Marketing Surveillance

Status: Completed

Phase of Trial: Phase IV

Latest Information Update: 06 Nov 2021

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Everolimus (Primary)
Indications Ischaemic heart disorders
Focus Adverse reactions
Acronyms XIENCE Xpedition SV Japan PMS
Sponsors Abbott Vascular

Most Recent Events

20 Apr 2021 Status changed from active, no longer recruiting to completed.
25 Sep 2018 Results of a pooled analysis from XIENCEV USA, XIENCEV Japan, XIENCE V China and XIENCE V India trials presented at the 30th Annual Scientific Symposium on Transcatheter Cardiovascular Therapeutics
11 Aug 2016 Planned primary completion date changed from 1 Mar 2016 to 1 Mar 2021.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com